Mpox rokotepullo. Mpox vaccine bottle.

Mpox

Page last reviewed 21.9.2026

The disease formerly known as monkeypox is now referred to as mpox.

There are two main clades of the mpox virus. The outbreak caused by clade II began in Europe and North America in summer 2022. The virus spread in particular through sex between men. In Finland, just under 50 cases were reported among adult men in 2022–2023. No new cases were detected after that until 2026.

In late summer 2026, a few mpox cases have been identified in the Helsinki metropolitan area. The infections detected so far have been caused by clade I of the virus. All of the cases have been identified in men who either had not been vaccinated against mpox or had received only one dose of the vaccine.

Two doses of the mpox vaccine provide good protection against infection with both clade I and clade II of the virus, although the protection is not complete. Infections can still occur in vaccinated people, but the illness is likely to be milder. One dose of the vaccine may also provide some protection. The highest risk of infection is among people who have not been vaccinated.

The mpox vaccine was offered free of charge to people at high risk of infection until autumn 2025

Mpox vaccinations in Finland have ended.

The mpox vaccine is currently not available in Finland (September 2026).

Health authorities are monitoring the mpox situation. If the number of cases increases to the level of an outbreak, the authorities will consider purchasing vaccines and restarting the vaccination program.

The vaccine used against mpox was offered to people who had been exposed to the virus, close contacts of people with mpox, and people at high risk of infection. Vaccinations began in Finland in autumn 2022. More than 3,000 mpox vaccine doses were administered in Finland between 2022 and 2025. The vaccine used in Finland also provides protection against disease caused by clade I.

Risk groups include:

  • Men who have sex with men and who have had several occasional sexual partners during the past six months
  • Men who use HIV preventive PrEP medication and have sex with men
  • Men who are awaiting PrEP treatment and have sex with men

Mpox in Europe 2022–2023

Mpox began spreading in 2022 in countries where the disease is not usually found. A significant proportion of cases have been linked to sex between men, particularly among people with multiple sexual partners. However, mpox is not a new disease. It is a viral disease that has been present in Central and West Africa for many years.

Since spring 2022, mpox cases have been reported in Europe among gay, bisexual, and other men who have sex with men. The highest numbers of cases have been reported in Spain, Germany, and the United Kingdom.

After vaccination began, the number of cases fell sharply in 2023. Since then, individual cases and small clusters of infections have continued to be reported in Europe.

Mpox cases in Finland

According to the Finnish Institute for Health and Welfare (THL), just under 50 mpox infections were reported in Finland between 2022 and the end of 2023. All cases were reported in men. No new cases were detected after that until 2026. In late summer 2026, a few mpox cases have been identified in the Helsinki metropolitan area. The cases detected so far have been caused by clade I. All of these cases have been reported in men who were either unvaccinated or had received only one dose of the vaccine.

Most mpox infections reported in Finland were acquired abroad.

Read here one person’s experiences on getting the mpox infection.

Symptoms of mpox typically include a fever, intense headache, muscle aches, back pain, low energy, swollen lymph nodes and a skin rash or lesions. Skin changes may appear on the face, hands, feet, mouth and/or in the genital or anus area (especially in cases where the infection was transmitted through sex).

The symptoms of mpox can be very diverse, and it can easily be confused with STIs. Mpox can have very mild symptoms. You should pay attention to skin changes, especially if you have recently had new sexual partners.

The typical incubation period is 6–13 days, but it can be up to 21 days. Symptoms typically last between 2 and 4 weeks and go away on their own without a treatment.

Mpox does not spread from one person to another very easily. Transmission requires close physical contact. Mpox can spread via close skin-to-skin contact during sex, including kissing, touching, oral and penetrative sex with someone who has symptoms.

The infection can be contracted through direct close contact with the skin changes of a sick person, for example through sexual contact as well as through droplets in a close face-to-face contact.

A condom protects against sexually transmitted infections, but against mpox it does not provide adequate protection. Clothing, bedding and towels that have been contaminated with the virus can also infect others.

There is a test for mpox. Mpox infection can be detected in laboratory tests of samples taken from skin changes using the gene amplification (PCR) method. In Finland, samples can be taken at healthcare services in any wellbeing services county.

It is important to note that the risk of mpox is not limited to men who have sex with men. Anyone who has close contact with someone who is infectious is at risk.

Having multiple casual sexual partners has been associated with an increased risk of mpox. However, given that the virus is being identified in these communities, learning about mpox will help ensure that as few people as possible are affected and that the outbreak can be stopped.

To prevent mpox, it is important to know how mpox spreads and what its symptoms are, so that you can get tested if necessary and avoid contact with others if you are infected.

Having multiple casual sexual partners has been associated with an increased risk of mpox. Mpox is known to spread at places and events where people have sex. If you wish to reduce the risk of mpox, you can consider reducing your sexual partners and consider avoiding places and events where people have sex.

It is good to know that the mpox situation in Finland is currently stable, while mpox is more common in many European countries. This is important to keep in mind when travelling abroad and after returning home. It is important to monitor your own and your partner’s symptoms and get tested if necessary.

A condom effectively protects against HIV and other sexually transmitted infections, but against mpox it does not provide adequate protection. Good hand hygiene and coughing hygiene reduce the risk of infection.

If you identify a new rash anywhere on your body, seek medical advice by calling your healthcare provider. If you live in Helsinki University Hospital area (HUS), you can contact the Genital diseases outpatient clinic. In other wellbeing services counties, you can contact the local on-call service by calling the emergency medical helpline.

If mpox is transmitted through sexual contact the rash may first appear around the genitals or the anus. Avoid having close contact with anyone until the rash is completely gone.

  • If possible, self-isolate and avoid close contact with others, unless advised otherwise by your healthcare provider.
  • Ask your close contacts and sexual partners if they have had similar symptoms.
  • If you notice a new rash on your partner’s body, including around the genitals and anus, talk with them and advise that they visit an STI clinic or consult a healthcare provider.

If your healthcare provider confirms you have mpox, follow their advice. Depending on the national recommendations, advice may include the following:

  • Take a break from sex.
  • Provide the health authorities with a list of events you have attended in the last 21 days so they can alert other community members who may have been infected.
  • Share the details of your close and sexual contacts with health authorities or get in touch with them directly so they can be informed and can protect themselves and others.

Mpox usually heals on its own and treatment is based on the symptoms. If necessary, pain and inflammation caused by blisters can be treated with various analgesics or anesthetic ointments and gels.

New antiviral medicines may be used in selected cases to treat severe mpox. However, their availability is limited.

Mpox vaccination in Finland ended in September 2025.

The Jynneos vaccine provides protection against both mpox and smallpox.

Health authorities are monitoring the mpox situation. If the number of cases increases to epidemic levels, the authorities will consider purchasing vaccines and restarting the vaccination program.

Poster with information about monkeypox
The poster was created in 2022, when mpox was still referred to by its former name, monkeypox.

WHO’s public health advice about mpox

Advice for gay men on recent outbreak on monkeypox
The public health advice for gay, bisexual and and other men who have sex with men on recent outbreak of mpox (WHO)